San Antonio carries a health burden that no major American city wants: an estimated 17% of Bexar County adults have diagnosed Type 2 diabetes — nearly double the national average of roughly 9%. Approximately 72% of adults are overweight or obese, compared to 42% nationally. An estimated 700,000 San Antonio residents have prediabetes — a reversible metabolic condition that, without effective intervention, progresses to diabetes in a significant fraction of cases. For years, the answer to these statistics was a combination of lifestyle counseling, older oral medications, and weekly injectable drugs that many patients found inconvenient or inaccessible due to cost. That landscape has now fundamentally changed.
In January 2026, Novo Nordisk launched the Wegovy pill — the first oral GLP-1 receptor agonist for obesity treatment in U.S. history. The once-daily pill contains semaglutide — the same active ingredient as the injectable Wegovy and Ozempic — and in the OASIS 4 Phase 3 clinical trial, produced a mean weight loss of 16.6% at 64 weeks, comparable to injectable Wegovy's performance. One in three patients achieved at least 20% weight loss. The self-pay price is $149 per month — significantly lower than most injectable GLP-1 alternatives. For San Antonio, one of the most diabetes-burdened cities in the United States, these numbers represent the most significant shift in obesity treatment access since the introduction of the first injectable semaglutide.
What the GLP-1 Revolution Has Already Done — and What the Pill Changes
"These drugs triple, even quadruple, what we could do with prior medications in the past," Dr. Aaron King, a Baptist Health System family medicine doctor in San Antonio, told the San Antonio Report earlier this year. "I would classify them as revolutionary." Dr. Alberto Chavez-Velazquez, an endocrinologist at the Texas Diabetes Institute who was involved in early primate research on GLP-1 drugs, noted that "although this class of medications has been on the market for decades to treat diabetes, their widespread use really took off in the last five years" — and that researchers are "uncovering a trove of health benefits that extend beyond weight management."
Those extended benefits are not marketing language — they are documented in major clinical trials. Injectable Wegovy's SELECT cardiovascular outcomes trial found that semaglutide reduced the risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% in adults with obesity and established heart disease. The FDA has approved the Wegovy pill for this cardiovascular indication as well. Heart disease is the leading cause of death in Bexar County. For the hundreds of thousands of San Antonio residents with obesity, diabetes, and cardiovascular disease simultaneously, a drug that addresses all three conditions in a single once-daily pill represents a clinical convergence that would have seemed implausible a decade ago.
The Medicare Expansion Changing Everything for Older San Antonians
The most consequential access change for San Antonio's large elderly and low-income population is not the pill's self-pay price reduction — it is a policy change taking effect in seven weeks. The Medicare GLP-1 Bridge program launches July 1, 2026, giving eligible Medicare beneficiaries access to Wegovy at a $50 monthly copay. This is the first time Medicare has broadly covered a GLP-1 drug for the obesity indication — a coverage change that has been debated for years and has finally become operational. For context: Medicare serves approximately 200,000 Bexar County residents. Of those, a substantial fraction are eligible for the Wegovy indication based on their obesity status and cardiovascular risk. The difference between $149 per month self-pay and $50 per month Medicare copay is the difference between affordable and out-of-reach for a fixed-income elderly resident in San Antonio's South Side or West Side communities.
Dr. Chavez-Velazquez's Vision: Preventing Diabetes Before It Starts
The most profound implication of effective, accessible GLP-1 therapy for San Antonio may not be treating existing diabetes — it may be preventing the next generation of it. "We do believe fully that these medications will essentially prevent the development of diabetes" in people with prediabetes and obesity, Dr. Chavez-Velazquez told the San Antonio Report. That prediction is grounded in data: GLP-1 medications in clinical trials have reduced new diabetes diagnoses in high-risk populations by 60–80% compared to placebo. For a city with an estimated 700,000 prediabetic residents, even a 50% reduction in progression rate would represent hundreds of thousands of diabetes diagnoses prevented over the coming decade — with the downstream reduction in kidney failure, amputations, blindness, and cardiovascular deaths that diabetes currently causes every year in Bexar County.
The Access Challenge That Remains
The good news is genuine and significant. The challenge is access in the communities that need it most. San Antonio's lowest-income neighborhoods — the South Side, the West Side, and the Westside corridor near Loop 410 — have the highest rates of obesity, the highest rates of diabetes, and the most limited access to primary care providers who prescribe GLP-1 medications. Many residents in these areas are uninsured or covered by Medi-Cal equivalents that have complex prior authorization requirements for GLP-1 drugs. The $149 self-pay price, while lower than injectable alternatives, remains a significant monthly expense for families near the poverty line.
San Antonio's Texas Diabetes Institute at University Health — described as the nation's leading diabetes care and research center and located on the South Side where the burden is highest — provides specialty diabetes care and can be reached through University Health's public health resources. For Medicare-eligible residents, the July 1 launch of the GLP-1 Bridge program should be the immediate priority: verify Medicare eligibility, discuss Wegovy candidacy with your primary care provider, and ask specifically about the $50 monthly copay option. For uninsured residents, Novo Nordisk's patient assistance program provides Wegovy at reduced or no cost to qualifying low-income individuals — information available at NovoCare.com. The drug exists. The evidence is overwhelming. Getting it to every San Antonio resident who needs it is the remaining work.
.png?w=600)
